Lord, Abbett & Co
PLRX icon

Lord, Abbett & Co’s Pliant Therapeutics PLRX Stock Holding History

Lord, Abbett & Co’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-455,823
Closed -$8.26M – 570
2023
Q2 		$8.26M Sell
455,823
-1,030,347
-69% -$24.4M 0.03% 435
2023
Q1 		$39.5M Buy
1,486,170
+985,382
+197% +$28.1M 0.14% 220
2022
Q4 		$9.68M Buy
500,788
+1,255
+0.3% +$26.2K 0.03% 428
2022
Q3 		$10.4M Buy
499,533
+180,774
+57% +$3.46M 0.04% 399
2022
Q2 		$2.55M Buy
318,759
+21,725
+7% +$139K 0.01% 533
2022
Q1 		$2.08M Buy
297,034
+5,220
+2% +$53.3K 0.01% 584
2021
Q4 		$3.94M Sell
291,814
-2,843
-1% -$45.2K 0.01% 566
2021
Q3 		$4.97M Sell
294,657
-3,936
-1% -$83.5K 0.01% 597
2021
Q2 		$8.7M Sell
298,593
-28,501
-9% -$887K 0.02% 551
2021
Q1 		$12.9M Buy
327,094
+137,690
+73% +$4.47M 0.03% 486
2020
Q4 		$4.3M Sell
189,404
-4,302
-2% -$108K 0.01% 603
2020
Q3 		$4.39M Buy
+193,706
New +$4.84M 0.01% 576

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Lord, Abbett & Co's PLRX Position: Q3 2023 in Review

Lord, Abbett & Co sold out of Pliant Therapeutics (PLRX) in Q3 2023, closing a stake of 455,823 shares — an estimated $8.26M sold.

Lord, Abbett & Co first reported a position in PLRX in Q3 2020 and held it in 12 quarters. The position peaked at $39.5M in Q1 2023. 136 funds tracked by Wall St. Rank hold PLRX as of Q3 2023.

  • Lord, Abbett & Co reported no remaining Pliant Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Lord, Abbett & Co sold 455,823 Pliant Therapeutics shares in Q3 2023, an estimated $8.26M.
  • Lord, Abbett & Co first reported a position in Pliant Therapeutics in Q3 2020 and held it in 12 quarters.
  • Lord, Abbett & Co's Pliant Therapeutics position peaked at $39.5M in Q1 2023.
  • 136 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2023.

Based on Lord, Abbett & Co's 13F filing for Q3 2023, filed 13 Nov 2023.